No Script

Please Wait...



AstraZeneca: Small Clot Risk after 1st COVID Shot, Less after 2nd

AstraZeneca: Small Clot Risk after 1st COVID Shot, Less after 2nd
folder_openMore from Europe access_time3 months ago
starAdd to favorites

By Staff- Agencies

AstraZeneca's COVID-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on Wednesday, after worries over side-effects.

The study, published in the Lancet medical journal, found that the estimated rate of thrombosis with thrombocytopenia syndrome [TTS] after the first dose was 8.1 per million in those inoculated, AstraZeneca said.

After the second dose of the vaccine, branded Vaxzevria and invented by Oxford University, the rate was 2.3 per million, comparable to that seen in unvaccinated people, the Anglo-Swedish company added.

AstraZeneca's shot has faced several setbacks, including production delays, and rare cases of severe side-effects, including TTS, which led to several countries restricting or stopping use of the vaccine, probes by regulators and warning labels.

The European Union's [EU] drugs regulator has been looking into cases of TTS since March and has found a possible link to Vaxzevria, and to Johnson & Johnson's single-dose COVID-19 shot. It has, however, maintained that overall benefits of both vaccines outweigh any risks posed by them.

“Wednesday's findings evaluated cases reported as of April 30 that occurred within 14 days of receiving the first or second dose, using AstraZeneca's global safety database,” it said.

Public focus has been high on the vaccine as it had been hailed as potentially the world's best weapon against the pandemic because it is cheap and easily transportable.

The study said limitations of the analysis included reliance on data provided by healthcare providers and those who got vaccinated, which might lead to under-reporting of cases.

It added that "heightened media attention might have led to event misclassification."